|
1
|
Saab R, Spunt SL and Skapek SX: Myogenesis
and rhabdomyosarcoma the Jekyll and Hyde of skeletal muscle. Curr
Top Dev Biol. 94:197–234. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dasgupta R and Rodeberg DA: Update on
rhabdomyosarcoma. Semin Pediatr Surg. 21:68–78. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Parham DM, Alaggio R and Coffin CM:
Myogenic tumors in children and adolescents. Pediatr Dev Pathol.
15(Suppl 1): S211–S238. 2012. View Article : Google Scholar
|
|
4
|
Ognjanovic S, Linabery AM, Charbonneau B
and Ross JA: Trends in childhood rhabdomyosarcoma incidence and
survival in the United States, 1975–2005. Cancer. 115:4218–4226.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Williamson D, Missiaglia E, de Reyniès A,
Pierron G, Thuille B, Palenzuela G, Thway K, Orbach D, Laé M,
Fréneaux P, et al: Fusion gene-negative alveolar rhabdomyosarcoma
is clinically and molecularly indistinguishable from embryonal
rhabdomyosarcoma. J Clin Oncol. 28:2151–2158. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen X, Stewart E, Shelat AA, Qu C,
Bahrami A, Hatley M, Wu G, Bradley C, McEvoy J, Pappo A, et al: St.
Jude Children’s Research Hospital-Washington University Pediatric
Cancer Genome Project: Targeting oxidative stress in embryonal
rhabdomyosarcoma. Cancer Cell. 24:710–724. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shukla N, Ameur N, Yilmaz I, Nafa K, Lau
CY, Marchetti A, Borsu L, Barr FG and Ladanyi M: Oncogene mutation
profiling of pediatric solid tumors reveals significant subsets of
embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in
growth signaling pathways. Clin Cancer Res. 18:748–757. 2012.
View Article : Google Scholar :
|
|
8
|
Shern JF, Chen L, Chmielecki J, Wei JS,
Patidar R, Rosenberg M, Ambrogio L, Auclair D, Wang J, Song YK, et
al: Comprehensive genomic analysis of rhabdomyosarcoma reveals a
landscape of alterations affecting a common genetic axis in
fusion-positive and fusion-negative tumors. Cancer Discov.
4:216–231. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Abraham J, Prajapati SI, Nishijo K,
Schaffer BS, Taniguchi E, Kilcoyne A, McCleish AT, Nelon LD, Giles
FG, Efstratiadis A, et al: Evasion mechanisms to Igf1r inhibition
in rhabdomyosarcoma. Mol Cancer Ther. 10:697–707. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Taylor JG VI, Cheuk AT, Tsang PS, Chung
JY, Song YK, Desai K, Yu Y, Chen QR, Shah K, Youngblood V, et al:
Identification of FGFR4-activating mutations in human
rhabdomyosarcomas that promote metastasis in xenotransplanted
models. J Clin Invest. 119:3395–3407. 2009.PubMed/NCBI
|
|
11
|
Crose LE and Linardic CM: Receptor
tyrosine kinases as therapeutic targets in rhabdomyosarcoma.
Sarcoma. 2011:7569822011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lee Y, Kawagoe R, Sasai K, Li Y, Russell
HR, Curran T and McKinnon PJ: Loss of suppressor-of-fused function
promotes tumorigenesis. Oncogene. 26:6442–6447. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Petricoin EF III, Espina V, Araujo RP,
Midura B, Yeung C, Wan X, Eichler GS, Johann DJ Jr, Qualman S,
Tsokos M, et al: Phosphoprotein pathway mapping: Akt/mammalian
target of rapamycin activation is negatively associated with
childhood rhabdomyosarcoma survival. Cancer Res. 67:3431–3440.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Guenther MK, Graab U and Fulda S:
Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK
pathway inhibition in rhabdomyosarcoma. Cancer Lett. 337:200–209.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hahn H, Wojnowski L, Specht K, Kappler R,
Calzada-Wack J, Potter D, Zimmer A, Müller U, Samson E,
Quintanilla-Martinez L, et al: Patched target Igf2 is indispensable
for the formation of medulloblastoma and rhabdomyosarcoma. J Biol
Chem. 275:28341–28344. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Marshall AD and Grosveld GC: Alveolar
rhabdomyosarcoma-The molecular drivers of PAX3/7-FOXO1-induced
tumorigenesis. Skelet Muscle. 2:252012. View Article : Google Scholar
|
|
17
|
Barr FG, Galili N, Holick J, Biegel JA,
Rovera G and Emanuel BS: Rearrangement of the PAX3 paired box gene
in the paediatric solid tumour alveolar rhabdomyosarcoma. Nat
Genet. 3:113–117. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Graf Finckenstein F, Shahbazian V,
Davicioni E, Ren YX and Anderson MJ: PAX-FKHR function as pangenes
by simultaneously inducing and inhibiting myogenesis. Oncogene.
27:2004–2014. 2008. View Article : Google Scholar
|
|
19
|
Keller C and Guttridge DC: Mechanisms of
impaired differentiation in rhabdomyosarcoma. FEBS J.
280:4323–4334. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Carlberg C: Gene regulation by melatonin.
Ann NY Acad Sci. 917:387–396. 2000. View Article : Google Scholar
|
|
21
|
Stehle JH, Saade A, Rawashdeh O, Ackermann
K, Jilg A, Sebestény T and Maronde E: A survey of molecular details
in the human pineal gland in the light of phylogeny, structure,
function and chronobiological diseases. J Pineal Res. 51:17–43.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hardeland R: Melatonin: Signaling
mechanisms of a pleiotropic agent. Biofactors. 35:183–192. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Challet E: Minireview: Entrainment of the
suprachiasmatic clockwork in diurnal and nocturnal mammals.
Endocrinology. 148:5648–5655. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Luchetti F, Betti M, Canonico B,
Arcangeletti M, Ferri P, Galli F and Papa S: ERK MAPK activation
mediates the antiapoptotic signaling of melatonin in UVB-stressed
U937 cells. Free Radic Biol Med. 46:339–351. 2009. View Article : Google Scholar
|
|
25
|
Luchetti F, Canonico B, Betti M,
Arcangeletti M, Pilolli F, Piroddi M, Canesi L, Papa S and Galli F:
Melatonin signaling and cell protection function. FASEB J.
24:3603–3624. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tengattini S, Reiter RJ, Tan DX, Terron
MP, Rodella LF and Rezzani R: Cardiovascular diseases: Protective
effects of melatonin. J Pineal Res. 44:16–25. 2008.
|
|
27
|
Zhang HM and Zhang Y: Melatonin: A
well-documented antioxidant with conditional pro-oxidant actions. J
Pineal Res. 57:131–146. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bukowska A: Anticarcinogenic role of
melatonin - potential mechanisms. Med Pr. 62:425–434. 2011.In
Polish.
|
|
29
|
Hrushesky WJ, Grutsch J, Wood P, Yang X,
Oh EY, Ansell C, Kidder S, Ferrans C, Quiton DF, Reynolds J, et al:
Circadian clock manipulation for cancer prevention and control and
the relief of cancer symptoms. Integr Cancer Ther. 8:387–397. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mao L, Yuan L, Slakey LM, Jones FE, Burow
ME and Hill SM: Inhibition of breast cancer cell invasion by
melatonin is mediated through regulation of the p38
mitogen-activated protein kinase signaling pathway. Breast Cancer
Res. 12:R1072010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mediavilla MD, Sanchez-Barcelo EJ, Tan DX,
Manchester L and Reiter RJ: Basic mechanisms involved in the
anti-cancer effects of melatonin. Curr Med Chem. 17:4462–4481.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Santoro R, Marani M, Blandino G, Muti P
and Strano S: Melatonin triggers p53Ser phosphorylation and
prevents DNA damage accumulation. Oncogene. 31:2931–2942. 2012.
View Article : Google Scholar
|
|
33
|
Schernhammer ES, Razavi P, Li TY, Qureshi
AA and Han J: Rotating night shifts and risk of skin cancer in the
nurses’ health study. J Natl Cancer Inst. 103:602–606. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fan L, Sun G, Ma T, Zhong F and Wei W:
Melatonin overcomes apoptosis resistance in human hepatocellular
carcinoma by targeting survivin and XIAP. J Pineal Res. 55:174–183.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liu L, Xu Y and Reiter RJ: Melatonin
inhibits the proliferation of human osteosarcoma cell line MG-63.
Bone. 55:432–438. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Trubiani O, Recchioni R, Moroni F,
Pizzicannella J, Caputi S and Di Primio R: Melatonin provokes cell
death in human B-lymphoma cells by mitochondrial-dependent
apoptotic pathway activation. J Pineal Res. 39:425–431. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hong Y, Won J, Lee Y, Lee S, Park K, Chang
KT and Hong Y: Melatonin treatment induces interplay of apoptosis,
autophagy, and senescence in human colorectal cancer cells. J
Pineal Res. 56:264–274. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jardim-Perassi BV, Arbab AS, Ferreira LC,
Borin TF, Varma NR, Iskander AS, Shankar A, Ali MM and de Campos
Zuccari DA: Effect of melatonin on tumor growth and angiogenesis in
xenograft model of breast cancer. PLoS One. 9:e853112014.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Jung-Hynes B, Schmit TL, Reagan-Shaw SR,
Siddiqui IA, Mukhtar H and Ahmad N: Melatonin, a novel Sirt1
inhibitor, imparts antiproliferative effects against prostate
cancer in vitro in culture and in vivo in TRAMP model. J Pineal
Res. 50:140–149. 2011.
|
|
40
|
Paroni R, Terraneo L, Bonomini F, Finati
E, Virgili E, Bianciardi P, Favero G, Fraschini F, Reiter RJ,
Rezzani R, et al: Antitumour activity of melatonin in a mouse model
of human prostate cancer: Relationship with hypoxia signalling. J
Pineal Res. 57:43–52. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Rubin BP, Nishijo K, Chen HI, Yi X,
Schuetze DP, Pal R, Prajapati SI, Abraham J, Arenkiel BR, Chen QR,
et al: Evidence for an unanticipated relationship between
undifferentiated pleomorphic sarcoma and embryonal
rhabdomyosarcoma. Cancer Cell. 19:177–191. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Borenfreund E and Puerner JA: Toxicity
determined in vitro by morphological alterations and neutral red
absorption. Toxicol Lett. 24:119–124. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Repetto G, del Peso A and Zurita JL:
Neutral red uptake assay for the estimation of cell
viability/cytotoxicity. Nat Protoc. 3:1125–1131. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Battistelli M, Salucci S, Burattini S and
Falcieri E: Further considerations on in vitro skeletal muscle cell
death. Muscles Ligaments Tendons J. 3:267–274. 2013.
|
|
45
|
Salucci S, Burattini S, Battistelli M,
Baldassarri V, Curzi D, Valmori A and Falcieri E: Melatonin
prevents chemical-induced haemopoietic cell death. Int J Mol Sci.
15:6625–6640. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Oltvai ZN, Milliman CL and Korsmeyer SJ:
Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that
accelerates programmed cell death. Cell. 74:609–619. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Youle RJ and Strasser A: The BCL-2 protein
family: Opposing activities that mediate cell death. Nat Rev Mol
Cell Biol. 9:47–59. 2008. View Article : Google Scholar
|
|
48
|
Chipuk JE, Moldoveanu T, Llambi F, Parsons
MJ and Green DR: The BCL-2 family reunion. Mol Cell. 37:299–310.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhang S, Zuo L, Gui S, Zhou Q, Wei W and
Wang Y: Induction of cell differentiation and promotion of endocan
gene expression in stomach cancer by melatonin. Mol Biol Rep.
39:2843–2849. 2012. View Article : Google Scholar
|
|
50
|
Sainz RM, Mayo JC, Tan DX, León J,
Manchester L and Reiter RJ: Melatonin reduces prostate cancer cell
growth leading to neuroendocrine differentiation via a receptor and
PKA independent mechanism. Prostate. 63:29–43. 2005. View Article : Google Scholar
|
|
51
|
Vijayalaxmi Thomas CR Jr, Reiter RJ and
Herman TS: Melatonin: From basic research to cancer treatment
clinics. J Clin Oncol. 20:2575–2601. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Panzer A and Viljoen M: The validity of
melatonin as an oncostatic agent. J Pineal Res. 22:184–202. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Lissoni P, Barni S, Mandalà M, Ardizzoia
A, Paolorossi F, Vaghi M, Longarini R, Malugani F and Tancini G:
Decreased toxicity and increased efficacy of cancer chemotherapy
using the pineal hormone melatonin in metastatic solid tumour
patients with poor clinical status. Eur J Cancer. 35:1688–1692.
1999. View Article : Google Scholar
|
|
54
|
Reiter RJ, Tan DX, Sainz RM, Mayo JC and
Lopez-Burillo S: Melatonin: Reducing the toxicity and increasing
the efficacy of drugs. J Pharm Pharmacol. 54:1299–1321. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Fan LL, Sun GP, Wei W, Wang ZG, Ge L, Fu
WZ and Wang H: Melatonin and doxorubicin synergistically induce
cell apoptosis in human hepatoma cell lines. World J Gastroenterol.
16:1473–1481. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Reiter RJ and Tan DX: What constitutes a
physiological concentration of melatonin? J Pineal Res. 34:79–80.
2003. View Article : Google Scholar
|
|
57
|
Venegas C, García JA, Escames G, Ortiz F,
López A, Doerrier C, García-Corzo L, López LC, Reiter RJ and
Acuña-Castroviejo D: Extrapineal melatonin: Analysis of its
subcellular distribution and daily fluctuations. J Pineal Res.
52:217–227. 2012. View Article : Google Scholar
|
|
58
|
Seabra ML, Bignotto M, Pinto LR Jr and
Tufik S: Randomized, double-blind clinical trial, controlled with
placebo, of the toxicology of chronic melatonin treatment. J Pineal
Res. 29:193–200. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Reiter RJ, Tan DX, Rosales-Corral S and
Manchester LC: The universal nature, unequal distribution and
antioxidant functions of melatonin and its derivatives. Mini Rev
Med Chem. 13:373–384. 2013.
|
|
60
|
Sainz RM, Mayo JC, Rodriguez C, Tan DX,
Lopez-Burillo S and Reiter RJ: Melatonin and cell death:
Differential actions on apoptosis in normal and cancer cells. Cell
Mol Life Sci. 60:1407–1426. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Wölfler A, Caluba HC, Abuja PM, Dohr G,
Schauenstein K and Liebmann PM: Prooxidant activity of melatonin
promotes fas-induced cell death in human leukemic Jurkat cells.
FEBS Lett. 502:127–131. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Bizzarri M, Proietti S, Cucina A and
Reiter RJ: Molecular mechanisms of the pro-apoptotic actions of
melatonin in cancer: A review. Expert Opin Ther Targets.
17:1483–1496. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Galano A, Tan DX and Reiter RJ: On the
free radical scavenging activities of melatonin’s metabolites, AFMK
and AMK. J Pineal Res. 54:245–257. 2013. View Article : Google Scholar
|
|
64
|
Bejarano I, Espino J, Barriga C, Reiter
RJ, Pariente JA and Rodríguez AB: Pro-oxidant effect of melatonin
in tumour leucocytes: Relation with its cytotoxic and pro-apoptotic
effects. Basic Clin Pharmacol Toxicol. 108:14–20. 2011. View Article : Google Scholar
|
|
65
|
Sánchez-Sánchez AM, Martín V,
García-Santos G, Rodríguez-Blanco J, Casado-Zapico S,
Suarez-Garnacho S, Antolín I and Rodriguez C: Intracellular redox
state as determinant for melatonin antiproliferative vs cytotoxic
effects in cancer cells. Free Radic Res. 45:1333–1341. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Büyükavci M, Ozdemir O, Buck S, Stout M,
Ravindranath Y and Savaşan S: Melatonin cytotoxicity in human
leukemia cells: Relation with its pro-oxidant effect. Fundam Clin
Pharmacol. 20:73–79. 2006. View Article : Google Scholar : PubMed/NCBI
|
